Rockwell Medical appoints Heather Hunter as chief operating officer

Rockwell Medical, Inc. (NASDAQ:RMTI) announced the appointment of Heather Hunter as Senior Vice President and Chief Operating Officer, effective immediately, according to a statement released Monday and based on a recent SEC filing. The micro-cap healthcare company, currently valued at $43.42 million, has shown resilience despite market challenges. According to InvestingPro data, analysts expect net income growth this year, with price targets ranging from $3 to $5 per share.

Hunter, age 46, previously served as the company’s Senior Vice President and Chief Corporate Affairs Officer since August 2022. Before joining Rockwell Medical , she was Vice President of Communications and Corporate Affairs at Venatorx Pharmaceuticals from January 2018 to August 2022. Earlier in her career, Hunter held various roles at Safeguard Scientifics (NYSE:SFE) and W.P. Carey (NYSE:WPC), including Vice President positions in marketing and corporate communications.

Hunter holds a B.A. in History from Yale University. She also serves as an advisory board member of Journal My Health and is a managing director at Golden Seeds, an angel investment firm.

Hunter’s employment agreement, initially established in August 2022 and amended in May 2025, provides for an annualized base salary of $323,574, eligibility for year-end performance bonuses with a target opportunity of 45% of base salary, and participation in the company’s benefit plans. She is also eligible for annual long-term incentive grants at the discretion of the board’s compensation committee.

Upon her initial employment, Hunter received a time-based option to purchase up to 60,000 shares of Rockwell Medical common stock, vesting in equal installments over four years. The agreement outlines terms for severance, including salary continuation and COBRA reimbursement for up to one year in the event of termination without cause or for good reason. In the case of a change of control, the agreement provides for accelerated vesting of equity awards and additional severance benefits.

Hunter has also entered into the company’s standard confidentiality, assignment of inventions, non-interference, and non-competition agreement.

This information is based on a press release statement included in the company’s SEC filing.

In other recent news, Rockwell Medical Inc. reported its second-quarter earnings for 2025, revealing a mixed financial performance. The company’s earnings per share (EPS) exceeded expectations, with a smaller-than-expected loss of $0.01 per share, against a forecasted loss of $0.05. However, the revenue did not meet projections, totaling $16.1 million compared to the anticipated $16.33 million. These recent developments indicate that while the company managed to control its losses better than expected, it struggled to achieve its revenue targets. The mixed results highlight the challenges Rockwell Medical faces in aligning its financial outcomes with market expectations. Investors may be particularly interested in how Rockwell Medical plans to address the revenue shortfall in future quarters. The company’s performance has sparked interest in how it will navigate the current financial landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.